US Office Of New Drugs Revamp Taking Shape: More Review Divisions Coming, But Who Will Lead Them?

FDA reaches final stages of reorganization that will better distribute an ever-increasing review workload; recent high-level departures will make filling even more management slots difficult.

FDA entrance sign 2016

The US FDA's reorganization of the Office of New Drugs will likely include the addition of several more review divisions to better manage the workload for division directors and their staff.

Increased responsibilities under the user fee system – plus FDA’s increased interest in engaging directly with patients – has resulted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet